Switch theme
Sign up to access all valuation multiples
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs and medical devices, modern pharmaceutical logistics system.
1997
1.5K+
Last FY Revenue $720M
Last FY EBITDA $55.0M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Kangmei Pharmaceutical Co. achieved revenue of $720M and an EBITDA of $55.0M.
Kangmei Pharmaceutical Co. expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kangmei Pharmaceutical Co. valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $720M | XXX | XXX | XXX |
| Gross Profit | XXX | $106M | XXX | XXX | XXX |
| Gross Margin | XXX | 15% | XXX | XXX | XXX |
| EBITDA | XXX | $55.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 8% | XXX | XXX | XXX |
| EBIT | XXX | $3.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 0% | XXX | XXX | XXX |
| Net Profit | XXX | $1.2M | XXX | XXX | XXX |
| Net Margin | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kangmei Pharmaceutical Co.'s stock price is CNY 2 (or $0).
Kangmei Pharmaceutical Co. has current market cap of CNY 27.3B (or $3.8B), and EV of CNY 26.6B (or $3.7B).
See Kangmei Pharmaceutical Co. trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kangmei Pharmaceutical Co. has market cap of $3.8B and EV of $3.7B.
Kangmei Pharmaceutical Co.'s trades at 5.1x EV/Revenue multiple, and 67.1x EV/EBITDA.
Equity research analysts estimate Kangmei Pharmaceutical Co.'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kangmei Pharmaceutical Co.'s P/E ratio is not available.
See valuation multiples for Kangmei Pharmaceutical Co. and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8B | XXX | $3.8B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 67.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 1037.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 3185.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -54.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKangmei Pharmaceutical Co.'s revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Kangmei Pharmaceutical Co.'s rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kangmei Pharmaceutical Co.'s rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kangmei Pharmaceutical Co. and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kangmei Pharmaceutical Co. acquired XXX companies to date.
Last acquisition by Kangmei Pharmaceutical Co. was XXXXXXXX, XXXXX XXXXX XXXXXX . Kangmei Pharmaceutical Co. acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kangmei Pharmaceutical Co. founded? | Kangmei Pharmaceutical Co. was founded in 1997. |
| Where is Kangmei Pharmaceutical Co. headquartered? | Kangmei Pharmaceutical Co. is headquartered in China. |
| How many employees does Kangmei Pharmaceutical Co. have? | As of today, Kangmei Pharmaceutical Co. has 1.5K+ employees. |
| Is Kangmei Pharmaceutical Co. publicy listed? | Yes, Kangmei Pharmaceutical Co. is a public company listed on SHG. |
| What is the stock symbol of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co. trades under 600518 ticker. |
| When did Kangmei Pharmaceutical Co. go public? | Kangmei Pharmaceutical Co. went public in 2001. |
| Who are competitors of Kangmei Pharmaceutical Co.? | Similar companies to Kangmei Pharmaceutical Co. include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kangmei Pharmaceutical Co.? | Kangmei Pharmaceutical Co.'s current market cap is $3.8B |
| Is Kangmei Pharmaceutical Co. profitable? | Yes, Kangmei Pharmaceutical Co. is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
